Impact BioMedical shares surge 44.69% after-hours as merger with Dr Ashleys extends to July 2026, securing 94.20% ownership via 169.56M shares.

Impact BioMedical (IBO) surged 44.69% in after-hours trading following the announcement of amendments to its merger agreement with Dr Ashleys Bio Labs Limited. The revised terms extended the merger deadline from March 31, 2026, to July 1, 2026, providing additional time to fulfill closing conditions and reducing short-term uncertainty. Under the updated agreement, IBO will receive 169.56 million PubCo Ordinary Shares, representing 94.20% of the combined company, and its parent company, DSS, Inc., secured 53,000 indemnification shares and potential additional shares contingent on funding obligations. These structural adjustments and extended timeline signaled improved clarity and alignment of interests, boosting investor confidence. The stock’s sharp rebound from a 52-week low further reflects optimism about the merger’s potential to enhance IBO’s equity position and operational flexibility.